Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use VIMOVO safely and effectively. See full prescribing information for VIMOVO. VIMOVO® (naproxen and esomeprazole magnesium) DELAYED RELEASE TABLETS Initial U.S. Approval: April 2010
Medication labelWhy this: Advisory · dailymed-prescription
VIMOVO is a combination product that contains naproxen and esomeprazole. It is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. VIMOVO is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products. Controlled studies do not extend beyond 6 months.
- generic_name
- naproxen and esomeprazole magnesium
- product_names
- NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
- ndc
- 16590-957, 0186-0510, 16590-957-30, 16590-957-60, 16590-957-90
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en